| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 08/09/2001 | WO2001057015A1 INTERNAL 1,15-LACTONES OF FLUPROSTENOL AND RELATED PROSTAGLANDIN F2α ANALOGS AND THEIR USE IN THE TREATMENT OF GLAUCOMA AND INTRAOCULAR HYPERTENSION |
| 08/09/2001 | WO2001057008A1 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
| 08/09/2001 | WO2001057002A1 Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same |
| 08/09/2001 | WO2001056994A1 Integrin antagonists |
| 08/09/2001 | WO2001056993A2 Pyrazole compositions useful as inhibitors of erk |
| 08/09/2001 | WO2001056987A1 Tosylproline analogs as thymidylate synthase inhibitors |
| 08/09/2001 | WO2001056972A1 Method for synthesis of n-[(s)-1-carboxybutyl]-(s)-alanine esters and use in synthesis of perindopril |
| 08/09/2001 | WO2001056590A2 Utilization of protein kinase inhibitor alpha |
| 08/09/2001 | WO2001056589A2 Physiologically active compositions of basidiomycotina and araliaceae extracts |
| 08/09/2001 | WO2001056577A1 Method of increasing alertness by administration of a vomeropherin, and vomeropherin-emitting alarm devices |
| 08/09/2001 | WO2001056576A1 Transdermal therapeutic system for the administration of zaleplon |
| 08/09/2001 | WO2001056573A1 Use of cox-2 inhibitors as gastroprokinetics |
| 08/09/2001 | WO2001056571A1 Treating allergic and inflammatory conditions |
| 08/09/2001 | WO2001056566A1 Neovascularization inhibitory compositions and method of inhibiting neovascularization |
| 08/09/2001 | WO2001056563A1 Adamantyl derivatives as anti-cancer agents |
| 08/09/2001 | WO2001056560A1 Substituted amino acids as neutral sphingomyelinase inhibitors |
| 08/09/2001 | WO2001056556A2 Dual inhibitors of cholesteryl ester and wax ester synthesis for sebaceous gland disorders |
| 08/09/2001 | WO2001056555A2 Use of cox-2 inhibitors for the treatment of constipation |
| 08/09/2001 | WO2001056552A2 Farnesyl protein transferase inhibitors for treating breast cancer |
| 08/09/2001 | WO2001056551A2 Method and formulation for treatment of vasoconstriction |
| 08/09/2001 | WO2001056541A1 Cosmetic preparations containing waltheria indica extracts |
| 08/09/2001 | WO2001056532A2 Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc) |
| 08/09/2001 | WO2001032596A8 Phenoxy carboxylic acid compounds and compositions for delivering active agents |
| 08/09/2001 | WO2001019337A3 Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing |
| 08/09/2001 | WO2001018004A3 PYRAZOLO[4,3-d]PYRIMIDINES |
| 08/09/2001 | WO2001016312A3 Nucleic acid based modulators of gene expression |
| 08/09/2001 | WO2001010834A9 Antibacterial agents |
| 08/09/2001 | WO2001007568A3 Muscle cells and their use in cardiac repair |
| 08/09/2001 | WO2001007066A3 Ppar delta inhibitors for the treatment of cardiovascular diseases |
| 08/09/2001 | WO2001005940A3 Methods for producing and preparing cells for cell therapy |
| 08/09/2001 | WO2001004318A3 Myxoma virus genes for immune modulation |
| 08/09/2001 | WO2000076452A3 Pharmaceutical compositions with wound healing or anti-complementary activity comprising a dextran derivative |
| 08/09/2001 | WO2000075144A8 Peroxynitrite decomposition catalysts and methods of use thereof |
| 08/09/2001 | WO2000073324A9 Modulation of gene expression in gastrointestinal inflammation |
| 08/09/2001 | WO2000071511A3 INHIBITORS OF FACTOR Xa |
| 08/09/2001 | WO2000071506A3 Naphthalene ureas as glucose uptake enhancers |
| 08/09/2001 | WO2000067728A3 Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same |
| 08/09/2001 | WO2000061729A3 Regulation of the expression of transcriptional repressor genes using nucleic acid molecules |
| 08/09/2001 | WO2000055072A3 Aerosol metering valve |
| 08/09/2001 | WO2000047554A3 INHIBITORS OF FACTOR Xa |
| 08/09/2001 | WO2000005224A3 Heterocyclic derivatives and their use as integrin inhibitor |
| 08/09/2001 | US20010012896 Crystallization, heating |
| 08/09/2001 | US20010012895 Therapy for hair loss in mammals; drug resistance; nervous system disorders |
| 08/09/2001 | US20010012858 Method for treating a patient with neoplasia by treatment with a platinum coordination complex |
| 08/09/2001 | US20010012856 Compositions and methods for the treatment of anorectal disorders |
| 08/09/2001 | US20010012854 Administering to the patient a diamide compound to induce apoptosis in tumor cells |
| 08/09/2001 | US20010012845 Adminstering an E-type prostaglandin ligand and a cyclooxygenase-2 enzyme selective inhibitor compound in combination with a carrier to treat inflammation |
| 08/09/2001 | DE19953517C1 Verwendung von Treosulfan zur Konditionierung von Patienten vor Knochemarktransplantation oder Blutstammzelltransplantation Use of treosulphan for conditioning of patients before Knochemarktransplantation or blood stem cell transplantation |
| 08/09/2001 | DE10004790A1 Plaster-form transdermal therapeutic system containing zaleplon, especially for use as hypnotic agent, providing safe and controlled drug delivery |
| 08/09/2001 | DE10003493A1 Preparing complexes of cyclodextrin and coenzyme Q10, are useful for treating cardiac or degenerative diseases, by homogenizing starting materials with an input of energy |
| 08/09/2001 | CA2400013A1 Methods of protein destabilization and uses thereof |
| 08/09/2001 | CA2399792A1 Substituted amino acids as neutral sphingomyelinase inhibitors |
| 08/09/2001 | CA2399686A1 Methods and materials relating to cub domain polypeptides and polynucleotides |
| 08/09/2001 | CA2399672A1 Methods and materials relating to metallocarboxypeptidase-like polypeptides and polynucleotides |
| 08/09/2001 | CA2399545A1 Pyrrolo-isoquinoline and tetrahydropyrrolo-isoquinoline derivatives and their use as mediators of the 5-ht7 receptor |
| 08/09/2001 | CA2399274A1 3-aminopyrazole inhibitors of cyclin dependent kinases |
| 08/09/2001 | CA2399214A1 Novel heterocyclic amide derivatives |
| 08/09/2001 | CA2399080A1 Humanized anti-ccr2 antibodies and methods of use therefor |
| 08/09/2001 | CA2399032A1 Ligands for fpr class receptors that induce a host immune response to a pathogen or inhibit hiv infection |
| 08/09/2001 | CA2399022A1 Ligand for vascular endothelial growth factor receptor |
| 08/09/2001 | CA2398889A1 Antisense modulation of survivin expression |
| 08/09/2001 | CA2398754A1 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
| 08/09/2001 | CA2398752A1 Tosylproline analogs as thymidylate synthase inhibitors |
| 08/09/2001 | CA2398674A1 Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same |
| 08/09/2001 | CA2398261A1 Treating allergic and inflammatory conditions |
| 08/09/2001 | CA2398255A1 Bcl-2-like polynucleotides, polypeptides, and antibodies |
| 08/09/2001 | CA2398250A1 Interaction of nmda receptor with protein tyrosine phosphatase |
| 08/09/2001 | CA2398219A1 Dual inhibitors of cholesterol ester and wax ester synthesis for sebaceous gland disorders |
| 08/09/2001 | CA2397790A1 Method of increasing alertness by administration of a vomeropherin, and vomeropherin-emitting alarm devices |
| 08/09/2001 | CA2396774A1 Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
| 08/09/2001 | CA2369076A1 Pyrazole compositions useful as inhibitors of erk |
| 08/08/2001 | EP1122257A1 Benzimidazole compounds as ORL1-receptor agonists |
| 08/08/2001 | EP1122254A2 4-Sulfonamide piperidine derivatives, method for their preparation and phamaceutical compositions containing them |
| 08/08/2001 | EP1122243A1 Novel imidazoles with anti-inflammatory activity |
| 08/08/2001 | EP1121939A2 Treatment of osteoporosis with EP2/EP4 receptor selective agonists |
| 08/08/2001 | EP1121938A2 Prevention of sudden infant death |
| 08/08/2001 | EP1121929A1 Drug preparation "histochrome" for treating ocular conditions |
| 08/08/2001 | EP1121926A1 Cosmetic preparations containing Waltheria indica extracts |
| 08/08/2001 | EP1121449A1 Delivery system for porcine somatotropin |
| 08/08/2001 | EP1121448A1 EXPRESSION AND SECRETION OF icIL-1 RECEPTOR ANTAGONIST TYPE II |
| 08/08/2001 | EP1121433A2 Human ankyrin family protein |
| 08/08/2001 | EP1121432A2 G-protein-coupled receptor-like proteins, polynucleotides encoded by them, and methods of using same |
| 08/08/2001 | EP1121431A1 Non-endogenous, constitutively activated human g protein-coupled receptors |
| 08/08/2001 | EP1121430A1 Human isre-binding protein |
| 08/08/2001 | EP1121427A1 (mbp1) polypeptides capable of interacting with oncogenic mutants of the p53 protein |
| 08/08/2001 | EP1121419A1 Tnfr related gene 12 |
| 08/08/2001 | EP1121381A2 Zinc finger binding domains for gnn |
| 08/08/2001 | EP1121372A1 Adenine derivatives |
| 08/08/2001 | EP1121369A1 Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection |
| 08/08/2001 | EP1121363A2 6-SUBSTITUTED PYRAZOLO 3,4-d]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS |
| 08/08/2001 | EP1121360A1 Il-8 receptor antagonists |
| 08/08/2001 | EP1121353A1 Benzazine derivatives as phosphodiesterase 4 inhibitors |
| 08/08/2001 | EP1121351A2 Preparation of (s)-2-amino-6,6-dimethoxyhexanoic acid methyl ester via novel dioxolanes |
| 08/08/2001 | EP1121156A2 Polymer conjugates of interferon beta- 1a and their uses |
| 08/08/2001 | EP1121140A2 Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease |
| 08/08/2001 | EP1121136A2 Methods of administering adenoviral vectors |
| 08/08/2001 | EP1121133A1 Methods for stimulating bone formation |
| 08/08/2001 | EP1121131A2 Atypical antipsychotic in combination with acetylcholinesterase inhibitor for improving cognition |
| 08/08/2001 | EP1121129A1 METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION |
| 08/08/2001 | EP1121128A1 A method of modulating ion channel functional activity |